Pancreatic cancer is fast becoming a global menace and it is projected to be the second
leading cause of cancer-related death by 2030. Pancreatic adenocarcinomas, which …

Pancreatic adenocarcinoma carries a devastating prognosis. For locally advanced and
metastatic disease, several chemotherapeutic regimens are currently being used. Over the …

The epithelial cell adhesion molecule (EpCAM) is a stem cell and carcinoma antigen, which
mediates cellular adhesion and proliferative signaling by the proteolytic cleavage. In …

Abstract Background Claudin 18.2 (CLDN18. 2) is a highly anticipated target for solid tumor
therapy, especially in advanced gastric carcinoma and pancreatic carcinoma. The T cell …

Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive
cancers with a very low survival rate at 5 years. The use of chemotherapeutic agents results …

Introduction Nanotechnology may open up new avenues for overcoming the challenges of
pancreatic cancer therapy as a broad arsenal of anticancer medicines fail to realize their full …

From lead 1,(N-(4-((4-(3-(4-(3-methoxyphenyl)-1H-1, 2, 3-triazol-1-yl) propyl) piperazin-1-yl)
sulfonyl)-phenyl) acetamide), a S100A2–p53 protein–protein interaction inhibitor based on …

Objective. Pancreatic cancer is one of the deadliest solid malignancies. Its surgical resection
is technically very challenging and has a high risk of complications even after discharge …

Despite recent advances in the prevention, diagnosis, and treatment of colorectal cancer as
the third cause of cancer death, the development of refractory tumor cells results in low …

Objectives Pancreatic ductal adenocarcinoma (PDAC) is characterized by occult onset,
rapid progression, and poor prognosis. CXC chemokines play an important role in tumor …